These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 1956209

  • 1. The disposition of antituberculous drugs in plasma of elderly patients. I. Isoniazid and hydrazine metabolite.
    Walubo A, Chan K, Woo J, Chan HS, Wong CL.
    Methods Find Exp Clin Pharmacol; 1991 Oct; 13(8):545-50. PubMed ID: 1956209
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Correlation between steady-state plasma concentration of antituberculous drugs and age, inclusion of rifampicin in the treatment regimen, adverse drug reactions and other clinical parameters.
    Woo J, Chan C, Chan R, Cheung W, Or K, Chan K.
    J Med; 1995 Oct; 26(5-6):279-94. PubMed ID: 8721904
    [Abstract] [Full Text] [Related]

  • 5. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J.
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
    [Abstract] [Full Text] [Related]

  • 6. Serum concentrations of rifampicin and isoniazid in tuberculosis.
    Seth V, Beotra A, Seth SD, Semwal OP, Kabra S, Jain Y, Mukhopadhya S.
    Indian Pediatr; 1993 Sep; 30(9):1091-8. PubMed ID: 8125594
    [Abstract] [Full Text] [Related]

  • 7. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
    Ahn HC, Lee YC.
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Type of isoniazid (INH) acetylation determined in tuberculosis patients treated at the Institute of Tuberculosis and Lung Diseases in Warsaw during the years 1990-1997].
    Augustynowicz-Kopeć E, Zwolska Z.
    Pneumonol Alergol Pol; 2002 Jun; 70(3-4):180-92. PubMed ID: 12271965
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess.
    Jutte PC, Rutgers SR, Van Altena R, Uges DR, Van Horn JR.
    Int J Tuberc Lung Dis; 2004 Nov; 8(11):1368-72. PubMed ID: 15581207
    [Abstract] [Full Text] [Related]

  • 14. The pharmacokinetics of isoniazid and hydrazine metabolite in plasma and cerebrospinal fluid of rabbits.
    Walubo A, Chan K, Wong CL.
    Methods Find Exp Clin Pharmacol; 1991 Apr; 13(3):199-204. PubMed ID: 2051844
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis.
    Jain A, Mehta VL, Kulshrestha S.
    Tuber Lung Dis; 1993 Apr; 74(2):87-90. PubMed ID: 8324212
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma.
    Smith PJ, van Dyk J, Fredericks A.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S325-8; discussion S351-2. PubMed ID: 10593712
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [The influence of rifampicin upon the metabolism of isoniazid (author's transl)].
    Modai J, Coulaud JP, Vivien JM, Berthelot G, Bergogne-Berezin E.
    Nouv Presse Med; 1978 Apr 15; 7(15):1263-7. PubMed ID: 662655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.